The Oncology Institute, Inc. filings document a public oncology-care company with Nasdaq-listed common stock under TOI and redeemable warrants under TOIIW. The warrant security is disclosed as exercisable, in whole-warrant form, for one share of common stock at an exercise price of $11.50 per share.
Recent Form 8-K reports furnish results of operations and financial-condition updates and record board-related governance events. Definitive proxy materials cover annual meeting procedures, shareholder voting matters and board governance for the company.
The Oncology Institute, Inc. reported strong first-quarter 2026 results with total operating revenue of $147.4 million, a 41% increase from the prior-year quarter, driven by capitated revenue growth and record performance in its pharmacy business.
Net loss narrowed sharply to $2.5 million from $19.6 million, and Adjusted EBITDA improved to negative $2.4 million from negative $5.1 million. Free Cash Flow was negative $2.4 million, better than negative $4.0 million a year earlier. Cash and cash equivalents were $30.3 million as of March 31, 2026.
For full-year 2026, the company reaffirmed guidance for revenue of $630–$650 million, gross profit of $97–$107 million, and Adjusted EBITDA of $0–$9 million, while raising Free Cash Flow guidance to $5–$15 million. It expects about $150 million in capitated revenue in 2026 and Q2 2026 Adjusted EBITDA between negative $1 million and positive $1 million.
The Oncology Institute, Inc. reported strong first-quarter 2026 results with total operating revenue of $147.4 million, a 41% increase from the prior-year quarter, driven by capitated revenue growth and record performance in its pharmacy business.
Net loss narrowed sharply to $2.5 million from $19.6 million, and Adjusted EBITDA improved to negative $2.4 million from negative $5.1 million. Free Cash Flow was negative $2.4 million, better than negative $4.0 million a year earlier. Cash and cash equivalents were $30.3 million as of March 31, 2026.
For full-year 2026, the company reaffirmed guidance for revenue of $630–$650 million, gross profit of $97–$107 million, and Adjusted EBITDA of $0–$9 million, while raising Free Cash Flow guidance to $5–$15 million. It expects about $150 million in capitated revenue in 2026 and Q2 2026 Adjusted EBITDA between negative $1 million and positive $1 million.
The Oncology Institute, Inc. reported total revenue of $147.4 million for the three months ended March 31, 2026, up from $104.4 million a year earlier, driven mainly by growth in specialty pharmacy and patient services.
The company posted a net loss of $2.5 million, a significant improvement from a $19.6 million loss in the prior-year quarter, with net loss per share narrowing to $0.02 from $0.21. Operating cash outflow was $2.2 million, and cash and cash equivalents were $30.3 million as of March 31, 2026. Long-term debt, primarily a senior secured convertible note, stood at $78.6 million net, while stockholders’ deficit was $16.3 million.
Management evaluated liquidity and, despite the accumulated deficit of $273.9 million, concluded the company has sufficient resources to fund operations for at least one year from issuance of these financial statements.
The Oncology Institute, Inc. reported total revenue of $147.4 million for the three months ended March 31, 2026, up from $104.4 million a year earlier, driven mainly by growth in specialty pharmacy and patient services.
The company posted a net loss of $2.5 million, a significant improvement from a $19.6 million loss in the prior-year quarter, with net loss per share narrowing to $0.02 from $0.21. Operating cash outflow was $2.2 million, and cash and cash equivalents were $30.3 million as of March 31, 2026. Long-term debt, primarily a senior secured convertible note, stood at $78.6 million net, while stockholders’ deficit was $16.3 million.
Management evaluated liquidity and, despite the accumulated deficit of $273.9 million, concluded the company has sufficient resources to fund operations for at least one year from issuance of these financial statements.
The Oncology Institute, Inc. has called a virtual annual stockholder meeting for June 17, 2026 at 11:00 a.m. Pacific Time, accessible via webcast at www.proxydocs.com/TOI. Stockholders of record as of April 24, 2026, representing 99,982,933 common shares, may vote.
Investors are being asked to elect eight directors, ratify BDO USA, P.C. as independent auditor for the year ending December 31, 2026, approve on an advisory basis executive compensation, and select the preferred frequency of future say-on-pay votes, with the Board recommending annual votes. The Board highlights a majority of independent directors, separated Chair and CEO roles, and standard board committees overseeing audit, compensation, governance and healthcare compliance. The proxy also details 2025 executive pay packages combining salary, performance-based cash bonuses tied to revenue, gross profit and Adjusted EBITDA, and time-vested equity awards.
The Oncology Institute, Inc. has called a virtual annual stockholder meeting for June 17, 2026 at 11:00 a.m. Pacific Time, accessible via webcast at www.proxydocs.com/TOI. Stockholders of record as of April 24, 2026, representing 99,982,933 common shares, may vote.
Investors are being asked to elect eight directors, ratify BDO USA, P.C. as independent auditor for the year ending December 31, 2026, approve on an advisory basis executive compensation, and select the preferred frequency of future say-on-pay votes, with the Board recommending annual votes. The Board highlights a majority of independent directors, separated Chair and CEO roles, and standard board committees overseeing audit, compensation, governance and healthcare compliance. The proxy also details 2025 executive pay packages combining salary, performance-based cash bonuses tied to revenue, gross profit and Adjusted EBITDA, and time-vested equity awards.
Oncology Institute, Inc. filed a Form 4 for Chief Administrative Officer Kristin England that shows no reportable insider trades during the period covered. The filing lists zero purchases, zero sales, zero derivative exercises, and no gifts, tax withholdings, or restructuring-related transfers.
Oncology Institute, Inc. filed a Form 4 for Chief Administrative Officer Kristin England that shows no reportable insider trades during the period covered. The filing lists zero purchases, zero sales, zero derivative exercises, and no gifts, tax withholdings, or restructuring-related transfers.
Oncology Institute, Inc. insider Jeffrey Langsam, the company’s Chief Clinical Officer, filed a Form 4 reporting his status as an officer but no transactions in company securities. The provided data show no purchases, sales, exercises, gifts, or other changes in his reported holdings.
Oncology Institute, Inc. insider Jeffrey Langsam, the company’s Chief Clinical Officer, filed a Form 4 reporting his status as an officer but no transactions in company securities. The provided data show no purchases, sales, exercises, gifts, or other changes in his reported holdings.
Oncology Institute, Inc. ten percent owner Jorey Chernett reported an open-market purchase of common stock. On April 9, 2026, Chernett bought 20,000 shares at $3.10 per share. After this purchase, Chernett directly owned 10,499,358 common shares.
Oncology Institute, Inc. ten percent owner Jorey Chernett reported an open-market purchase of common stock. On April 9, 2026, Chernett bought 20,000 shares at $3.10 per share. After this purchase, Chernett directly owned 10,499,358 common shares.
Langsam Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Clinical Officer, Jeffrey Langsam, received a grant of 70,270 shares of common stock in the form of restricted stock units. These RSUs were granted at no cash cost per share and increase his direct holdings to 127,650 shares after the award.
The footnote explains that one quarter of the RSUs will vest on the first anniversary of the Vesting Commencement Date, with the remaining units vesting in three equal annual installments on each of the next three anniversaries. All RSUs are subject to continued service with the company through the respective vesting dates.
Langsam Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Clinical Officer, Jeffrey Langsam, received a grant of 70,270 shares of common stock in the form of restricted stock units. These RSUs were granted at no cash cost per share and increase his direct holdings to 127,650 shares after the award.
The footnote explains that one quarter of the RSUs will vest on the first anniversary of the Vesting Commencement Date, with the remaining units vesting in three equal annual installments on each of the next three anniversaries. All RSUs are subject to continued service with the company through the respective vesting dates.
England Kristin reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Administrative Officer Kristin England received a grant of 55,743 shares of common stock in the form of restricted stock units (RSUs) at no cash cost. Following this award, she directly holds 153,780 shares of the company’s common stock.
The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting commencement date and the remaining three quarters vesting in equal annual installments on each of the next three anniversaries, subject to her continued service with the company.
England Kristin reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Administrative Officer Kristin England received a grant of 55,743 shares of common stock in the form of restricted stock units (RSUs) at no cash cost. Following this award, she directly holds 153,780 shares of the company’s common stock.
The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting commencement date and the remaining three quarters vesting in equal annual installments on each of the next three anniversaries, subject to her continued service with the company.
Podnos Yale reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Medical Officer, Yale Podnos, received a grant of 66,446 shares of common stock on March 27, 2026 at no cost as part of a restricted stock unit (RSU) award. According to the terms, one quarter of the RSUs vest on the first anniversary of the vesting commencement date, with the remaining portions vesting in three equal annual installments so that all units vest by the fourth anniversary, subject to continued service. The issuer also executed a sale of 16,173 shares at $3.07 per share to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026, a mechanistic tax-related transaction rather than an open-market trade.
Podnos Yale reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Medical Officer, Yale Podnos, received a grant of 66,446 shares of common stock on March 27, 2026 at no cost as part of a restricted stock unit (RSU) award. According to the terms, one quarter of the RSUs vest on the first anniversary of the vesting commencement date, with the remaining portions vesting in three equal annual installments so that all units vest by the fourth anniversary, subject to continued service. The issuer also executed a sale of 16,173 shares at $3.07 per share to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026, a mechanistic tax-related transaction rather than an open-market trade.